Search
Nitazoxanide
go.drugbank.com/drugs/DB00507ApprovedInvestigationalVet approvedThis drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. … Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment
Products: N/aBimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigational[A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment … Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.
Benznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. … [L939] It is the first treatment made available in the United States for Chagas disease.
Oteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalApproved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.
Ceruletide
go.drugbank.com/drugs/DB00403ApprovedIt exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles. … Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin.
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalIn June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023. … [A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family.
Coagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalHowever its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Vinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalIn 2009, vinflunine was approved by the European Medicines Agency (EMA) as a second-line therapy of metastatic and advanced urothelial cancer after failure of platinum-based treatment [A32626]. … It was first described in 1998 at the Pierre Fabre research center in France.
Oxyphencyclimine
go.drugbank.com/drugs/DB00383ApprovedOxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.
N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)
go.drugbank.com/drugs/DB11202ApprovedIt is found in sanitizing solutions or soaps as an active ingredient due to its antimicrobial properties. … N-alkyl ethylbenzyl dimethyl ammonium (c12-c14) is a quaternary ammonium compound with surfactant properties.
Synonyms: N-alkyl ethylbenzyl dimethyl ammonium (C12-C14), N-alkyl ethylbenzyl dimethyl ammonium (C12-C14) cationSalts: N-alkyl ethylbenzyl dimethyl ammonium chloride (C12-C14)